Clinical Research Directory

Inclusion Criteria: * 18≤Age≤80, any sex. * Failure to wean from CPB or refractory cardiogenic shock after cardiac surgery. Failure to wean from CPB is defined as failed to discontinue CPB or post-weaning CI \<2.2L/min/m2 + PCWP \>15mmHg, despite optimal pre-weaning management and receiving at least one high dose inotrope. Refractory cardiogenic shock is defined as a condition that occurs despite adequate fluid status and meets all the following criteria: ① CI\<2.2L/min/m2 + PCWP\>15mmHg despite receiving at least one high dose inotrope or IABP; OR SBP \<80mmHg or MAP\<50mmHg despite receiving at least one high dose intrope + high dose norepinephrine or IABP. * Presence of at least one signs indicating hypoperfusion: decreased mentation; cold, clammy, ashen or cyanotic extremities or skin or livedo reticularis; urine output\<30ml/h or 0.5ml/kg/h; or lactate\>2mmol/L or metabolic acidosis. * Patient has signed the informed consent form. Exclusion Criteria: * Body surface area\>2.5m2. * Presence of any cardiac assist device (other than an IABP). * Right ventricular failure. * Evidence of any vascular disease or anatomy precluding placement or deployment of the device (e.g. severely calcified vessel). * Evidence of ventricular thrombus. * Moderate or severe aortic valve insufficiency/stenosis, or severe aortic valve calcification. * Presence of mechanical aortic valve or cardiac contractile device. * Obstructive, hypertrophic cardiomyopathy. * Presence of uncorrected ventricular septal defect, atrial septal defect or patent foramen ovale. * Mechanical manifestation of AMI (e.g. ventricular septal rupture, papillary muscle rupture, ventricular rupture). * Any hematological disorder causing fragility of blood vessel or hemolysis. * Known allergy or intolerant to heparin. * Presence or suspicion of active systemic infection. * Cardiopulmonary resuscitative maneuver lasting longer than 20 minutes before device placement. * Sustained or non-sustained ventricular tachycardia or ventricular fibrillation unresponsive to medical therapy. * Severe hepatic dysfunction, renal failure or severe respiratory failure * Pregnant or lactating female. * Concomitant enrollment in another investigational drug or device study where the primary endpoint has not yet been completed or that will clinically interfere with the endpoint of this investigation. * Other conditions considered unsuitable for participating in this investigation by the investigators.